Company ProfilePremium

Cosnine Co., Ltd.

Company Profile Analysis

Ticker: 082660.KQ주식회사 코스나인

ESOMAR 23 Corporate BadgeISO Certifications Badge
Cosnine Co., Ltd. - Company showcase

Year Founded & Workforce

2001

69 Employees

Cosnine Co., Ltd. logo

Cosnine Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Cosnine Co., Ltd. Overview

ItemDetailSource
Legal name주식회사 코스나인 / Cosnine Co., Ltd.Korean Wikipedia; KRX disclosures
Former namesChamtech (참테크) → Chamtech Global (참테크글로벌) → Crucial MS (크루셜엠스) → Samwoo MS (삼우엠스) → 9Complex (나인컴플렉스, from June 2019) → Cosnine (from 2020)Korean Wikipedia; IB Tomato (2021); Saramin
FoundingIncorporation date given as 20 June 2001. Some media say the company was founded in 2000 as a telecom-equipment maker. The sources conflict and both are noted.Korean Wikipedia; Saramin; Bloter (23 Apr 2025); IB Tomato
FounderLee Ki-hong (이기홍)Korean Wikipedia
Incorporation jurisdictionRepublic of Korea (주식회사)—
Headquarters address27 Hagunsandan 2-ro, Yangchon-eup, Gimpo-si, Gyeonggi-do, South Korea. The Gimpo land and buildings were sold in January 2025 (see Section 8).Korean Wikipedia; Simply Wall St
Exchange / tickerKOSDAQ: 082660 (A082660). Listed 5 Oct 2005; delisted 21 Sep 2026.Korean Wikipedia; KRX/DART 8 Sep 2026
ISINKRX standard construction gives KR7082660002, but this was not checked against a registry.—
CUSIPNot applicable (no US listing)—
Fiscal year end31 DecemberKIND filings
Employees69–75 per aggregators (mid/late 2024)Simply Wall St; Google Finance
Auditor (FY2025)Daesung Accounting Corp. (대성회계법인). Opinion: disclaimer.FY2025 annual report (KIND, 24 Mar 2026)
Auditor (FY2024)The company received a disclaimer of opinion on 21 Mar 2025.Cosinkorea (11 Apr 2025)
Interim reviewer (H1 FY2023)Samdo Accounting Corp. (삼도회계법인). Review conclusion: unqualified.Top Daily (16 Aug 2023)
Market capitalisationLast pre-suspension value KRW 47.83bn, at KRW 480/share × 99.64M shares (7 Aug 2024). There is no current market value since delisting.Google Finance; Simply Wall St
Shares outstanding99.64M (2024)Google Finance; Simply Wall St
Websitewww.cosnine.com—
Corporate status flagStartup database THE VC lists the company status as "closed" (폐업). This is not confirmed by a primary source.thevc.kr

Cosnine Co., Ltd. is a former KOSDAQ-listed South Korean contract cosmetics manufacturer. It produced skincare and colour cosmetics on an OEM/ODM/OCM basis from a CGMP- and ISO 22716-certified plant in Gimpo, Gyeonggi-do. The plant included an underground production line, which was a first for the Korean industry.

The listed shell traces back to Chamtech, a 2000s telecom-equipment and handset-case maker. It changed its name five times before absorbing the cosmetics maker Cosnine in December 2019 and adopting its name in 2020. Its best-known product heritage is the Gerissong horse-oil cream, reported at more than 30 million units sold.

After 2020 the company never earned an operating profit. Revenue shrank from about KRW 21bn (FY2020) to about KRW 9.7bn (FY2024). Governance failures followed: control contests, alleged embezzlement of KRW 9.08bn by former management, consecutive audit disclaimers, an abandoned court rehabilitation, and finally delisting in September 2026. Today it is best characterised as a distressed, delisted entity with no demonstrated going-concern value.


What the company does

At its operating peak, Cosnine was a contract development and manufacturing organisation (CDMO) for cosmetics. It operated under three engagement models:

OEM: manufacturing to the client's formula.

ODM: Cosnine develops and manufactures the product.

OCM: a broader service that includes concept and brand support.

Aggregator business descriptions (Simply Wall St, citing S&P Global data) list two product families:

Basic skincare: creams, serums, toners, essences, lotions, moisturisers, eye creams and sunscreens.

Make-up: foundations, CC/BB creams, concealers, blushes, eyeshadows, eyeliners, mascaras, lipsticks and lip glosses.

The company also stated:

  • It had obtained quasi-drug (의약외품) manufacturing and sales authorisation.

  • It held Halal certification.

  • It held patents related to horse-oil (마유) formulations (Etoday, 2019).

Saramin's registry summary lists three registered activities: cosmetics manufacturing; metal can and other packaging-container manufacturing; and cosmetics and toiletries wholesale.

Ancillary and attempted businesses

BusinessDescriptionPeriodEvidence
ITS / "Smart" businessBuilding and maintaining intelligent transport information systemsLegacy from earlier incarnations; still reported in 2020–2022Asia Economy (7 Oct 2020); Dealsite (20 Jul 2022)
China cosmetics distributionDistribution and sales via the Shanghai subsidiary (Cosnine Shanghai)c.2020–2024Dealsite (20 Jul 2022; 24 Jul 2024)
Lithium carbonate distribution and solarThrough subsidiary Green Energy Innovation, set up 21 Jul 2023. Letters of intent for lithium carbonate supply with Shandong Nanbeiji New Energy; supply talks with another Chinese group.2023 onwardTop Daily (16 Aug 2023)
AI, hydrogen, hotel/tourismArticles of incorporation amended for these new businesses after the July 2024 change of control2024 (aspirational)Dealsite (24 Jul 2024)
Mobile-phone cases (legacy)Original handset-case manufacturing. The company exited because of poor results.Pre-2019Asia Economy (7 Oct 2020); THE VC

Revenue model

Revenue came mainly from product sales of contract-manufactured cosmetics, invoiced per unit or order to brand-owner clients. ITS maintenance contracts generated small service revenue. There was no subscription or licensing revenue of note.

Cosmetics accounted for:

94%: of revenue in H1 2020 (Asia Economy, 7 Oct 2020)

64.1%: of revenue in 2019, the year of the Cosnine merger (IB Tomato)

  • about 95% of revenue in 2020 (IB Tomato)

Value-chain position and customers

Cosnine sat in the midstream manufacturing layer of the K-beauty value chain. Its position looked like this:

Upstream: raw-material and packaging suppliers.

Its own layer: formulation, filling and packaging.

Downstream: brand owners, who sell through road-shops, duty-free, e-commerce and export channels. Cosnine itself sold into China through its Shanghai unit.

Named counterparties in public sources:

  • Chinese conglomerate Bunma Group (contract-manufacturing and distribution cooperation, 2022).

  • Genomics company Clinomics (bio-based anti-ageing cosmetics MOU, 2023).

The company's customer list, customer concentration, and end-market split were not publicly disclosed in the sources reviewed.

Company self-description vs independent characterisation

Company's description. In its last public positioning, Cosnine described itself as a CGMP- and ISO-based cosmetics manufacturer building out OEM, ODM and OCM capabilities (medigatenews, 27 Jun 2023). In 2023, management said it expected a revenue rebound from:

  • the end of Korea's indoor mask mandate, and

  • China's reopening.

Management argued that simply returning to 2020 revenue would mean two to three times growth (Dealsite, 20 Jan 2023).

Independent characterisation. The evidence points to a sub-scale, chronically loss-making contract manufacturer:

Negative gross margins: FY2022 −24.75%, FY2023 −4.00%, FY2024 about −11.9%.

Little pricing power or utilisation: much of the plant was reportedly idle during COVID-19 (Dealsite, 20 Jul 2022).

Diversification without results: repeated moves into unrelated businesses (lithium, AI, hydrogen, hospitality) produced no disclosed revenue.

Fragile governance: The FY2025 annual report contains a disclaimer of opinion. FY2025 operating revenue is therefore not reliably verifiable.

Strategy

Stated strategy (themes, paraphrased)

The latest annual report's strategy section could not be retrieved; the report was filed under a disclaimer. Disclosed strategic themes over the last cycle were:

  1. Cosmetics recovery (2023). Use the end of the mask mandate and China's reopening. Pursue aggressive marketing of K-beauty basic and colour lines. Improve the production environment and introduce smart logistics (Dealsite, 20 Jan 2023).

  2. Diversification into new energy (2023). Lithium carbonate distribution to Korean conglomerates and a solar business via Green Energy Innovation (Top Daily, 16 Aug 2023).

  3. Post-change-of-control agenda (2024). Strengthen cosmetics while adding AI, hydrogen and hotel/tourism businesses (Dealsite, 24 Jul 2024). Market commentators doubted near-term results.

  4. Restructuring for survival (2024–2025). Pursue court rehabilitation. Sell the Gimpo real estate (KRW 14.0bn). Seek convertible-bond issuance or further asset sales to repay short-term debt (Cosinkorea, 11 Apr 2025). Run a pre-plan M&A through a third-party share allotment with Samjong KPMG as advisor (Bloter, 23 Apr 2025).

Initiatives register (last ~24 months)

DateInitiativeTypeOutcome
Jul 2024Change of control to SMG Youngmin Songdo; board overhaul; new business purposesGovernance / diversificationNo disclosed revenue from new businesses
28 Oct 2024Improvement plan to KRX; rehabilitation petitionRestructuringRehabilitation commenced 26 Nov 2024; abolished 12 Aug 2025
Jan 2025Sale of Gimpo land and buildings (KRW 14.0bn)Asset disposalCompleted
Mar–Apr 2025Pre-plan M&A (third-party allotment)Capital raising / saleFailed (court, Aug 2025)
4 Aug 2025Company applies to abolish rehabilitation, saying liquidation was more advantageousWind-downGranted 12 Aug 2025
1 Dec 2025Injunction against delistingLegal defenceDismissed; delisted 21 Sep 2026

Medium-term targets and guidance

No medium-term financial targets or guidance are publicly disclosed for the current period.

Historical aspirations went unmet:

2016: the pre-merger CEO targeted KRW 100bn of revenue quickly and KRW 200bn within five years (Etoday, 21 Sep 2016). Actual peak revenue was about KRW 21bn in FY2020.

2022: the company said Bunma Group cooperation would bring sharp revenue growth and a likely profit from Q3 2022 (Dealsite, 20 Jul 2022). FY2022 posted an operating loss of about KRW 7.7bn.

ESG and cost programmes

No sustainability commitments or formal cost-reduction targets were identified. The company claimed a 20% cut in administrative expenses in H1 2023 (Top Daily, 16 Aug 2023).

Products & Services

The table below uses aggregator descriptions and press disclosures. Pricing was not disclosed for any line.

Cosmetics — contract manufacturing (OEM/ODM/OCM)

Product categoryDescriptionTarget customerLaunch / latestPricing
Skin creams and moisturisersBasic skincare emulsions and creams, including horse-oil (mayu) creamsBrand owners (domestic and China)——
Serums and essencesTreatment-type skincareBrand owners——
Toners and lotionsBasic skincare liquidsBrand owners——
Eye creamsTargeted skincareBrand owners——
SunscreensSun care. May fall under quasi-drug authorisation; this is not confirmed per SKU.Brand owners——
Foundations, CC and BB creams, concealersBase make-upBrand owners——
Blushes, eyeshadows, eyeliners, mascarasColour make-upBrand owners——
Lipsticks and lip glossesLip colourBrand owners——

Category list source: Simply Wall St (S&P Global description).

Flagship and heritage products

ProductDescriptionEvidence
Gerissong 9 Complex (게리쏭 9컴플렉스) horse-oil creamHit product of the pre-merger Cosnine. Reported cumulative sales of more than 30 million units; the company continued producing it. Supported by horse-oil-related patents.Etoday (2019); Etoday (21 Sep 2016)
Bio-based anti-ageing cosmetics (with Clinomics)Joint R&D under the June 2023 MOU, using Clinomics genomics-derived anti-ageing researchMedigatenews (27 Jun 2023)

Quality and regulatory credentials

CredentialDetailSource
CGMP (Korea MFDS)Post-certification renewal assessment rated "compliant" (c.2019)Etoday (2019)
ISO 22716International cosmetics GMP standardEtoday (2019)
Halal certificationObtainedEtoday (2019)
Quasi-drug manufacturing and sales authorisationObtainedEtoday (2019)

Non-cosmetics offerings

OfferingDescriptionStatus
ITS construction and maintenanceIntelligent transport information systemsLegacy; revenue not disclosed
Lithium carbonate distributionSourcing from Chinese suppliers for sale to Korean conglomeratesAnnounced 2023; revenue not disclosed
Solar businessVia Green Energy InnovationAnnounced 2023; revenue not disclosed

Financial Narrative

Income statement (FY2020–FY2024)

Sources and notes:

FY2020–FY2023: revenue and cost of sales from Hankyung Markets (consolidated). Operating income, EBITDA and net income are derived from Hankyung's reported margins (operating margin, EBITDA margin, net margin) multiplied by revenue.

Media cross-checks: operating losses were reported as KRW 5.3bn (2021), KRW 7.7bn (2022) and KRW 6.5bn (2023) by Dealsite and Cosinkorea. These match the derived values.

FY2024: from the FY2025 annual report comparatives (KIND). These appear to be separate-entity statements. Cosinkorea reported a consolidated FY2024 operating loss of about KRW 8.3bn.

FY2023 basis difference: the FY2025 report's FY2023 separate comparatives show operating loss KRW −6,114M, pre-tax KRW −6,043M and net KRW −6,063M. Consolidated net loss (derived) is KRW −5,878M.

Dividends: none paid (Stockopedia: no current dividend). FY2020–FY2022 zero values reflect accumulated deficits and losses; no dividend was identified in any source.

FY2025: full-year audited figures are not reliable because of the disclaimer. Aggregated quarterly data (Google Finance) show revenue of KRW 1,680M (Q1), KRW 1,870M (Q2) and KRW 1,340M (Q3). That is KRW 4,890M for the first nine months. Quarterly operating losses were KRW −2,110M, −1,630M and −1,490M.

Margins and growth

Notes:

  • FY2020–FY2023 ratios as reported by Hankyung Markets.

  • FY2024 ratios are computed from the FY2025 annual report comparatives.

  • Revenue CAGR FY2020–FY2024 is −17.5% a year (computed: (9,741 / 21,016)^(1/4) − 1).

Balance sheet (available data points)

Notes:

FY2023 equity (derived): the KRW 9.08bn embezzlement was disclosed as 26.19% of FY2023 equity, which implies equity of about KRW 34.7bn.

FY2024 total assets (derived): the KRW 14.0bn Gimpo sale was disclosed as 26.87% of total assets, which implies about KRW 52.1bn.

FY2024 short-term borrowings: KRW 12.0bn (Cosinkorea).

Accumulated deficit and capital impairment: KRW 82.1bn deficit and 55% impairment at end-2024 (Bloter, 23 Apr 2025). Cosinkorea separately reported impairment above 50%.

Data integrity flag. At 30 June 2024, equity was reported at KRW 32.4bn, with cash exceeding debt. By year-end 2024 there was a capital impairment above 50% and KRW 12.0bn of short-term borrowings.

The deterioration in six months coincides with:

  • the embezzlement findings,

  • an FY2024 net loss of KRW 19.4bn, and

  • "other losses" of KRW 9.4bn in FY2024 (FY2025 annual report comparatives).

The auditor's disclaimer means none of these balances is assured.

Goodwill and intangibles, working capital, net debt and the long-term debt split were not publicly disclosed in the sources reviewed. For context, KRW 5.4bn of goodwill arose from the 2019 Cotis and Cosnine acquisitions, of which KRW 2.5bn was impaired in H1 2020 (Asia Economy).

Cash flow

Cash-flow statements were not publicly disclosed in retrievable form. Disclosed funding events instead show a business financed externally:

  • third-party share allotments (KRW 5bn in 2020; a 2024 rights issue of undisclosed size),

  • convertible bonds (series 20 and 21 were being re-sold in 2023), and

  • asset sales (Gimpo plant, KRW 14.0bn, January 2025).

In H1 2023, the company reported repaying KRW 13.9bn of current borrowings that carried a 9.5% interest rate (Top Daily, 16 Aug 2023).

Ratios

Notes:

  • ROE and ROA from Hankyung Markets.

  • FY2024 interest expense of about KRW 300M from Cosinkorea.

  • Debt to equity: Simply Wall St reported 25.0% at 30 June 2024, down from 285.6% five years earlier. These are point estimates, not fiscal year-end values.

  • ROIC, current ratio, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle were not publicly disclosed. Net debt/EBITDA and interest coverage are not meaningful with negative EBITDA.

Commentary on trends and drivers

Revenue collapse after 2020. Revenue peaked in FY2020 at about KRW 21.0bn. It fell 40% in FY2021 and 28% in FY2022, then stabilised near KRW 9.6–9.7bn in FY2023–FY2024. Three drivers explain the decline:

Mask-related demand: management linked the downturn to COVID-19 and mask mandates, which hurt colour cosmetics in particular (Dealsite, 20 Jan 2023).

Idle capacity: much of the production capacity sat unused.

China: the China distribution channel weakened (Dealsite, 24 Jul 2024).

The hoped-for 2023 reopening rebound was marginal: FY2023 revenue rose only 6.8%.

Structural negative gross margin. Gross margin turned negative in FY2022 (−24.75%) and stayed negative. A cosmetics manufacturer whose cost of sales exceeds revenue for three consecutive years is running below break-even utilisation. Fixed plant costs cannot be absorbed at about KRW 10bn of annual sales. By contrast, large ODM peers report positive double-digit gross margins.

Operating loss as a multiple of revenue. Operating losses equalled 68–86% of revenue in FY2022–FY2024. SG&A was KRW 6.9bn on KRW 9.7bn of revenue in FY2024 (FY2025 annual report comparatives). The company ran losses for eight consecutive years from 2017 to 2024 (Bloter, 23 Apr 2025). Dealsite described the run as seven consecutive years of losses by mid-2024.

Below-the-line volatility. In FY2024, the net loss of KRW 19.4bn was more than twice the operating loss. The gap came from:

  • other losses of KRW 9.4bn, and

  • finance costs of KRW 8.0bn, against finance income of KRW 5.9bn.

FY2023 finance income of KRW 12.0bn and finance costs of KRW 8.4bn point to large derivative or convertible-bond valuation swings.

Inflection points:

  • FY2020: the cosmetics pivot lifted revenue.

  • FY2021: governance conflict and the collapse in demand.

  • FY2024: embezzlement, audit disclaimer and rehabilitation.

  • FY2025: liquidation-value finding by the court.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment / Line Details

Segment / lineContentsStatus

Cosmetics manufacturing and sales

OEM/ODM/OCM skincare and make-up; own-brand heritage products (Gerissong horse-oil line)

Core; about 94–95% of revenue in 2020

Smart / ITS

Build and maintenance of intelligent transport information systems

Minor; residual share of revenue

China distribution

Cosnine Shanghai: distribution of cosmetics in China

Reported as weakening by 2024

New energy (Green Energy Innovation)

Lithium carbonate distribution, solar

Launched 2023; no disclosed revenue

Revenue by Segment

SegmentFY2019FY2020FY2021FY2022

Cosmetics revenue (KRW Mn, Dealsite series)

7,30019,20010,700—

Cosmetics revenue (KRW Mn, IB Tomato series)

—21,400——

Total revenue (KRW Mn, consolidated)

—21,01612,5458,998

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Group Entities

EntityRelationshipFunctionStatus

Cosnine Co., Ltd.

Parent (former KOSDAQ issuer)

Cosmetics manufacturing

Delisted 21 Sep 2026

Cosnine Shanghai Co., Ltd.

Subsidiary

China cosmetics distribution

Reported in difficulty (Dealsite, 24 Jul 2024); current status not disclosed

Green Energy Innovation (그린에너지이노베이션)

Subsidiary (est. 21 Jul 2023)

Lithium carbonate distribution, solar

Current status not disclosed

Tianjin Samwoo MS

Former subsidiary

Handset cases (China)

Divested c.2020

Cotis Co.

Merged Jul 2019

Cosmetics-related

Absorbed

Cosnine (pre-merger)

Merged 16 Dec 2019

Cosmetics manufacturing

Absorbed

City Package (시티패키지)

Merged (June; year not stated in source)

Packaging

Absorbed

Income Statement and Per-Share Data

MetricFY2020FY2021FY2022FY2023FY2024

Revenue (KRW Mn)

21,01612,5458,9989,6089,741

Cost of sales (KRW Mn)

18,17911,25511,2269,99210,900

Gross profit (KRW Mn)

2,8371,290-2,228-384-1,159

Operating income (KRW Mn)

-1,818-5,263-7,693-6,529-8,088

EBITDA (KRW Mn, derived)

-273-3,711-6,291-5,266—

Pre-tax income (KRW Mn)

———-6,043-19,397

Net income (KRW Mn)

-11,471-17,040-10,768-5,878-19,406

Basic EPS (KRW)

———-77-209

Dividends per share (KRW)

00000

Margin Analysis (%)

MetricFY2020FY2021FY2022FY2023FY2024

Gross margin (%)

13.5010.28-24.75-4.00-11.90

Operating margin (%)

-8.65-41.95-85.50-67.95-83.03

EBITDA margin (%)

-1.30-29.58-69.91-54.81—

Net margin (%)

-54.58-135.83-119.67-61.18-199.22

Revenue growth YoY (%)

—-40.31-28.276.781.38

Balance Sheet and Margin Analysis (%)

MetricFY2023FY2024

Total assets (KRW Mn)

—52,103

Total equity (KRW Mn)

34,670—

Short-term borrowings (KRW Mn)

—12,000

Accumulated deficit (KRW Mn)

—82,100

Capital impairment ratio (%)

—55

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Analysis

Item (KRW Mn)Value

Total assets

49,460

Total liabilities

17,040

Shareholders' equity

32,410

Total debt

8,110

Cash

14,450

Net cash

6,340

Short-term assets

21,100

Short-term liabilities

16,800

Long-term liabilities

251

Financial Analysis (Annual)

MetricFY2020FY2021FY2022FY2023FY2024

Dividends paid (KRW Mn)

00000

Returns & Leverage Ratios (%) and Key Financials

RatioFY2020FY2021FY2022FY2023FY2024

ROE (%)

-60.36-82.08-46.91-20.25—

ROA (%)

-16.43-27.92-21.45-11.72—

Interest expense (KRW Mn)

————300

Revenue by Region

RegionFY2022FY2023FY2024

Total (KRW Mn)

8,9989,6089,741

Capital Markets

ItemValueSource

Last price before suspension

KRW 480 (7 Aug 2024)

Google Finance; Stockopedia

Market cap at suspension

KRW 47.83bn

Google Finance; Simply Wall St

52-week range (to Aug 2024)

KRW 256–630 per Simply Wall St; KRW 437–485 per Google Finance (sources conflict)

Simply Wall St; Google Finance

Liquidation trading

10–18 Sep 2026 (7 sessions)

KRX/DART

Delisting date

21 Sep 2026

KRX/DART

Share Price & Returns

PeriodReturn (%)

1 year

-20.13

3 years

-64.58

5 years

-82.22

Since IPO

-98.83

Valuation Multiples

MultipleCosnine

P/E (TTM)

-2.30

P/S (TTM)

4.7

P/B

10.21

Capital Markets — Dividend history / policy

ItemStatus

Dividend history / policy

No dividends paid (Stockopedia)

Buyback authorisations

None identified

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

Not publicly disclosed. KRW 12.0bn of short-term borrowings at end-2024. CB series 20 and 21 existed in 2023.

Dilution

Shares outstanding grew about 15% in the year to 2024 (Simply Wall St)

Analyst Conclusions

Management guidance and consensus

There is no current management guidance and no consensus. The last forward-looking statements came in 2022–2023 (China cooperation, mask-mandate recovery, lithium distribution), and none was delivered.

Bull case (low probability)

  1. Asset recovery. The court's finding that liquidation value exceeds going-concern value implies residual asset value. Remaining equipment, IP (horse-oil patents, Gerissong know-how) and receivables could deliver some recovery to creditors. Equity recovery is unlikely given the 55% capital impairment.

  2. Legal recoveries. Successful prosecution and civil recovery of the alleged KRW 9.08bn embezzlement (about 26% of FY2023 equity) could add value to the estate.

  3. Strategic buyer for assets. A distressed acquirer could buy the certified manufacturing know-how cheaply. Peers such as IcuRe show that turnarounds of small ODMs are possible (IcuRe moved to its first operating profit in nine years in Q1 2026 after restructuring).

Bear case (base case)

  1. Terminal wind-down. The court abolished rehabilitation on 12 August 2025 because liquidation was worth more than continuing operations. Delisting followed on 21 September 2026. Under Korean insolvency law, the next step after abolition may be bankruptcy proceedings; their commencement is not publicly confirmed.

  2. No operating economics. Gross margins were negative for three consecutive years. The owned plant was sold in January 2025. Nine-month FY2025 revenue was only about KRW 4.9bn (aggregator, unaudited).

  3. Uninvestable reporting. Disclaimers of opinion for FY2024 and FY2025 mean no figure from 2024 onward is assured. That deters any counterparty, lender or investor.

Catalysts and monitorables (next 12 months)

MonitorableWhy it matters
Any bankruptcy or liquidation filing / court declarationDefines creditor and shareholder outcomes
Outcome of the criminal case against former management (KRW 9.08bn)Potential estate recovery
Sale of residual assets (equipment, IP, subsidiaries)Liquidation proceeds
Minority shareholder litigationPossible claims against former directors or controlling shareholders
Status of Cosnine Shanghai and Green Energy InnovationHidden liabilities or assets
Any OTC trading arrangement or shareholder noticeLiquidity for former shareholders

Analyst verdict

Cosnine is a case study in how a fragile listed shell, repeated reinvention and weak governance can destroy value in a sector that was otherwise booming.

The listed entity began as Chamtech in the early 2000s. It moved through telecom equipment and handset cases under four names before absorbing the cosmetics maker Cosnine in December 2019. The pivot briefly lifted revenue to about KRW 21bn in FY2020, with cosmetics about 95% of sales. That was the high-water mark.

The business never reached break-even utilisation. Revenue more than halved by FY2022, and gross margin turned negative and stayed there. Operating losses equalled roughly 70–85% of revenue in FY2022–FY2024.

Governance compounded the operating weakness:

  • a 2022 proxy fight with its own largest shareholder,

  • an internal-control failure and caution designation,

  • an alleged KRW 9.08bn embezzlement by former management,

  • disclosure violations and an unpaid fine,

  • two consecutive audit disclaimers.

The January 2025 sale of the Gimpo plant real estate raised KRW 14bn but removed the company's core physical asset. The court-supervised M&A, run with Samjong KPMG, found no investor. The Seoul Rehabilitation Court then concluded in August 2025 that the company was worth more liquidated than operating. Delisting followed on 21 September 2026 after the company's injunction was dismissed.

The contrast with the industry is stark. Kolmar Korea and Cosmax each set record revenue of about KRW 2.4–2.7tn in FY2025 on global indie-brand demand. Cosnine shows that participation in a growth market is no substitute for scale, utilisation and credible stewardship.

For any stakeholder, the relevant questions now concern estate recovery rather than enterprise value: the outcome of the embezzlement case, the realisation of residual assets, and the treatment of creditors. Equity holders should assume minimal recovery. Absent a primary-source development such as an audited statement, a confirmed asset buyer, or a court outcome, the entity should be treated as non-operating and in wind-down.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure / datesBackgroundSource

Kim Bo-hyung (김보형)

Representative Director (CEO), per Korean Wikipedia

Joined board Jul 2024

Director at IS E-commerce, a domestic and overseas shopping purchase-agency company

Korean Wikipedia; Dealsite (24 Jul 2024)

Woo Jeong-min (우정민)

Listed as representative by THE VC

Dates not disclosed

—

thevc.kr

Jeong Hye-yoon (정혜윤)

Inside director

From Jul 2024

CEO of J Cosmedic (cosmetics industry)

Dealsite (24 Jul 2024)

Cho Woo-jin (조우진)

Inside director

From Jul 2024

Head of duty-free business, Hwacheong Group

Dealsite (24 Jul 2024)

Shin Ho-sang (신호상)

Outside director

From Jul 2024

Director, FKTU Scholarship & Culture Foundation

Dealsite (24 Jul 2024)

Park Sung-jin (박성진)

Outside director

From Jul 2024

CEO, Fandom Korea

Dealsite (24 Jul 2024)

Court-appointed custodian (관리인)

Rehabilitation custodian

26 Nov 2024 – 12 Aug 2025

Name not disclosed in sources

Cosinkorea (14 Aug 2025)

“—” = not publicly disclosed.

Executive Leadership Team

NameFormer roleTenureNotesSource

Baek Gwang-yeol (백광열)

CEO, later co-CEO

Jun 2019 – Jul 2024

Re-appointed at the June 2022 EGM. Named with four others in the Nov 2024 KRW 9.08bn embezzlement complaint. Age 52 (aggregator). Held 1.78% (aggregator, 2024).

Saramin; Dealsite; Simply Wall St

Lee Dong-wook (이동욱)

Vice President

c.2022

Led the Bunma Group cooperation

Dealsite (20 & 22 Jul 2022)

Moon Sung-hyuk (문성혁)

Outside director

Resigned Jul 2024

Voluntary resignation

Dealsite (24 Jul 2024)

Choi Young-kwon (최영권)

Inside director (IcuRe nominee)

From c.2021

Then CEO of IcuRe. Later indicted at IcuRe in a separate breach-of-trust case (2025).

Dealsite (22 Jul 2024); Hankyung (30 Jun 2026)

Kim Hyung-tae (김형태)

CEO of pre-merger Cosnine

c.2016

Set the KRW 200bn five-year revenue target

Etoday (21 Sep 2016)

"Chairman Lee" (이모 회장)

Chairman (surname only disclosed)

2,024

Filed the July 2024 complaint against Baek

Dealsite (12 Nov 2024)

Major Shareholders

HolderSharesStake (%)Date / source

SMG Youngmin Songdo Co., Ltd.

8,020,0008.05

Simply Wall St (2024). Dealsite reported 8.3% on the July 2024 change of control.

Bioline Value Investment Union

3,640,2193.65

Simply Wall St (2024). Dealsite reported 3.8% after the 2024 rights issue.

IcuRe Pharmaceutical

2,760,0002.77

Simply Wall St (2024). Possibly stale; see discrepancy note below.

Baek Gwang-yeol (former CEO)

1,772,0001.78

Simply Wall St (2024)

General public

83,447,60683.7

Simply Wall St (2024)

Minority shareholder coalition (ACT platform)

—6.59

185 shareholders pooled votes (Dealsite, 12 Nov 2024)

Competitive Landscape

Key Competitors

CompetitorSegment overlapScale indicatorRelative positioning vs CosnineSource

Kolmar Korea (한국콜마)

Full-range skincare / make-up ODM

FY2025 revenue KRW 2,722.4bn; operating profit KRW 239.6bn

#1–2 domestic ODM; about 280× Cosnine's FY2024 revenue

Kukinews (26 Feb 2026)

Cosmax (코스맥스)

Full-range ODM, global plants

FY2025 revenue KRW 2,398.8bn (+10.7%); operating profit KRW 195.8bn

#1–2 domestic ODM; China, US and Southeast Asia plants

Kukinews (26 Feb 2026)

Cosmecca Korea (코스메카코리아)

Skincare / make-up ODM (Korea, US via Englewood Lab, China)

Q3 2025 revenue KRW 182.4bn

Industry #3

Hanwha Investment (7 Nov 2025); Alphadistill

C&C International (씨앤씨인터내셔널)

Colour cosmetics (lip, point make-up) ODM

Top-4 ODM by 2024 revenue

Direct overlap in colour cosmetics

Cosinkorea (24 Apr 2025)

IcuRe (아이큐어)

Cosmetics ODM plus TDDS pharma

2025 revenue KRW 82.8bn; Q1 2026 separate revenue KRW 32.1bn with first operating profit in 9 years

Former Cosnine strategic investor; small-cap ODM peer

Hankyung (10 May 2026; 30 Jun 2026)

Yuhan Cosmetic (유한코스메틱, formerly Coson)

Skincare ODM backed by Yuhan Corp.

—

Small-cap peer that also went through rehabilitation; renamed Oct 2025

Hankyung (27 Oct 2025); Dailypharm

ENCOS (엔코스)

Emerging ODM

—

Cited as a fast-growing new ODM

Alphadistill

SD Biotechnologies (에스디생명공학)

Cosmetics / health foods

Heavy losses (KRW 34.8bn in 2021, 38.0bn in 2022)

Distressed peer with an audit disclaimer

Asia Economy (28 Mar 2023)

Clinomics / Celestra (셀레스트라)

Bio-cosmetics (adjacent)

Audit disclaimer for FY2024

Former partner; distressed

iNews24 (2025)

Peer Comparison FY2025

MetricCosnine (FY2024)Kolmar Korea (FY2024)Cosmax (FY2024)IcuRe (FY2025)

Revenue (KRW Bn)

9.72,452.12,166.182.8

Revenue growth YoY (%)

1.414.021.965.6

Operating profit (KRW Bn)

-8.1195.6175.4—

Operating margin (%)

-83.08.08.1—

Recent Developments

The window covers April 2025 to October 2026. All identified items are listed, plus two context items from early 2025.

Company Snapshot

$7.1M

Revenue

69

Employees

2001

Founded

Gimpo, South Korea

Headquarters

SWOT Analysis

Strengths

  • Regulatory credentials. CGMP renewal rated compliant, plus ISO 22716, Halal and quasi-drug authorisation (Etoday, 2019).
  • Purpose-built facility (historically). A KRW 30bn plant with an underground, climate-controlled line and automation, claimed as a Korean first (Etoday, 2016; 2019).
  • Proven hit-product know-how. More than 30 million units of Gerissong 9 Complex sold, plus horse-oil patents (Etoday, 2019).
  • Minority shareholder engagement. Shareholders backed management against the largest shareholder in the June 2022 EGM, about 20M of 49M shares (Dealsite, 24 Jun 2022). In 2024, a 6.59% minority bloc organised on the ACT platform (Dealsite, 12 Nov 2024).
  • Ability to raise funds by asset sales. The Gimpo real estate realised KRW 14.0bn, equal to 26.87% of total assets (Cosinkorea).
  • Ability to lower debt in some periods. KRW 13.9bn of 9.5% borrowings repaid in H1 2023 (Top Daily). Simply Wall St also reported debt/equity falling from 285.6% to 25% over five years to mid-2024.

Weaknesses

  • Structural unprofitability. Eight consecutive years of losses from 2017 to 2024 and an accumulated deficit of KRW 82.1bn (Bloter, 23 Apr 2025).
  • Negative gross margin. −24.75% (FY2022), −4.00% (FY2023), about −11.9% (FY2024) (Hankyung; FY2025 annual report).
  • Revenue contraction. KRW 21.0bn (FY2020) to KRW 9.7bn (FY2024), a CAGR of −17.5%.
  • Financial reporting failure. Disclaimers of opinion for FY2024 and FY2025 (Cosinkorea; KIND).
  • Capital impairment. About 55% at end-2024, above the 50% threshold (Bloter; Cosinkorea).
  • Goodwill destruction. KRW 2.5bn of KRW 5.4bn acquisition goodwill impaired within a year of the 2019 deals (Asia Economy, 7 Oct 2020).

Opportunities

  • Most of these are historical or now largely foreclosed.
  • K-beauty export growth. Industry leaders posted record FY2025 results (Kukinews, 26 Feb 2026). In principle, there is demand for capacity.
  • Asset value of residual IP and equipment in any liquidation or asset sale. The court found liquidation value above going-concern value (Cosinkorea, 14 Aug 2025).
  • Legal recovery from former management. The KRW 9.08bn embezzlement complaint (Dealsite, 6 Nov 2024) could yield recoveries.
  • Bio-cosmetics niche through the Clinomics R&D tie-up (Medigatenews, 2023).
  • China partnerships such as Bunma Group (Dealsite, 2022), if the business were to be restarted.
  • Distressed-asset buyer interest. A formal sale process through Samjong KPMG was run in 2025 (Bloter). It failed, but it shows how a buyer could be sought.

Threats

  • Delisting completed. 21 September 2026 (KRX/DART), which removes access to equity capital markets.
  • Liquidation risk. The court abolished rehabilitation because liquidation value exceeded going-concern value (Cosinkorea, 14 Aug 2025).
  • Litigation exposure. Embezzlement and breach-of-trust matters, plus possible minority shareholder claims after delisting.
  • Competitive scale gap. Peers are 200–280 times larger by revenue.
  • Regulatory tightening. KOSDAQ rule changes in 2026 would have pressured a re-listing or KONEX path, for example the KRW 1,000 minimum price (Insight, 25 Sep 2026).
  • Counterparty and creditor actions. KRW 12.0bn of short-term borrowings at end-2024 (Cosinkorea), with no going-concern financing.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Jan 2025 (context)Gimpo land and buildings sold for KRW 14.0bn Cosinkorea; S-econMain operating asset monetised; capacity to manufacture in-house impaired
Jan 2025 (context)Aggravated penalty points for the unpaid disclosure fine add a substantive-review ground S-econ (28 Nov 2025)Compounding listing risk
21 Mar 2025Disclaimer of opinion on FY2024 statements: audit evidence not provided, going-concern uncertainty, embezzlement effects Cosinkorea (11 Apr 2025)A second, independent delisting ground
Late Mar 2025Pre-plan M&A permission application submitted to the court Bloter (23 Apr 2025)Attempt to recapitalise
9 Apr 2025Corrected audit report filed CosinkoreaConfirms the disclaimer
10 Apr 2025Objection to the delisting ground filed; additional improvement period runs to about April 2026 CosinkoreaBuys time
23 Apr 2025Samjong KPMG reported as sale advisor; third-party allotment structure expected BloterM&A process begins
4 Aug 2025Company applies to abolish rehabilitation, citing funding limits and falling sales Cosinkorea (14 Aug 2025)Management concedes liquidation is more advantageous
12 Aug 2025Seoul Rehabilitation Court abolishes rehabilitation (case 2024회합100174): liquidation value exceeds going-concern value and M&A failed Cosinkorea (14 Aug 2025)Effectively ends the going-concern path
13 Aug 2025KRX states the abolition is a ground for substantive listing review CosinkoreaAccelerates delisting
10 Oct 2025Improvement period expires (as reported) Cosinkorea; S-econLeads to the delisting determination
28 Nov 2025KOSDAQ delisting determination; liquidation trading scheduled 2–10 Dec 2025 and delisting 11 Dec 2025 S-econ (28 Nov 2025)Delisting decided
1 Dec 2025Injunction filed at Seoul Southern District Court; liquidation trading suspended Bloter (Dec 2025)Delays delisting
24 Mar 2026FY2025 annual report filed. Auditor Daesung issues a disclaimer on separate and consolidated statements. Audit fee KRW 220M; 1,370 planned hours. KIND (24 Mar 2026)Second consecutive disclaimer
9 Apr 2026KRX year-end market measures: Cosnine among 11 KOSDAQ companies with a second consecutive year of delisting grounds Bizwatch (9 Apr 2026)Delisting reconfirmed
Jul 2026 (context)KOSDAQ maintenance thresholds tightened: market-cap floor raised to KRW 20bn; new delisting route for shares below KRW 1,000 Insight (25 Sep 2026); MTN (2 Oct 2026)The last price (KRW 480) and market cap (KRW 47.8bn) imply exposure to the penny-stock rule had trading continued
14 Aug 2026KRX notice: additional ground for management-issue designation KRX/DART via ChickstockFurther deterioration
25 Aug 2026Correction to the board resolution convening a shareholders' meeting KRX/DART via Chickstock–
8 Sep 2026Court dismisses the injunction; liquidation trading resumes KRX/DART 20260908900606Delisting path cleared
8 Sep 2026Trading suspension lifted for liquidation trading: 10–18 Sep 2026 (7 sessions); delisting date 21 Sep 2026 KRX/DART 20260908900609Final trading window
10–18 Sep 2026Liquidation trading KRX–
21 Sep 2026Delisted from KOSDAQ KRX; DatatoozaEnd of public-market status
2 Oct 2026 (context)Seoul Southern District Court suspends market-cap-based delisting decisions for other issuers MTN (2 Oct 2026)Not applicable to Cosnine, whose delisting rested on qualitative grounds (going concern and management transparency)

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Total revenue fell from KRW 21,016 Mn in FY2020 to KRW 8,998 Mn in FY2022.
Cosnine Co., Ltd. — Revenue by Segment
Series (KRW Mn)FY2019FY2020FY2021FY2022
Total revenue—21,01612,5458,998
Cosmetics revenue7,30019,20010,700—
Cosmetics revenue—21,400——

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. 1KRX/DART – Cosnine liquidation trading and delisting notice (rcpNo 20260908900609), via Chickstock — 8 Sep 2026 (chickstockfi.com)
  2. 2Datatooza – Cosnine delisting; 7-day liquidation trading — 8 Sep 2026 (datatooza.com)
  3. 3KIND – Cosnine FY2025 annual report (제25기) — 24 Mar 2026 (kind.krx.co.kr)
  4. 4Bizwatch – 54 KOSPI/KOSDAQ companies at delisting crossroads — 9 Apr 2026 (news.bizwatch.co.kr)
  5. 5S-econ – Cosnine delisting decision; liquidation trading — 28 Nov 2025 (s-econ.kr)
  6. 6Bloter – Cosnine files injunction with Seoul Southern District Court — Dec 2025 (bloter.net)
  7. 7Cosinkorea – Rehabilitation abolished; delisting and liquidation — 14 Aug 2025 (cosinkorea.com)
  8. 8Bloter – Cosnine put up for M&A (Samjong KPMG) — 23 Apr 2025 (bloter.net)
  9. 9Cosinkorea – Disclaimer of opinion; delisting ground — 11 Apr 2025 (cosinkorea.com)
  10. 10iNews24 / Daum – KOSDAQ Market Committee delisting resolution — 18 Dec 2024 (v.daum.net)
  11. 11Cosinkorea – Embezzlement; delisting crisis — Nov 2024 (cosinkorea.com)
  12. 12Dealsite – Rehabilitation commencement — 2 Dec 2024 (dealsite.co.kr)
  13. 13Dealsite – Renewed embezzlement complaint — 12 Nov 2024 (dealsite.co.kr)
  14. 14Dealsite – KRW 9bn embezzlement complaint — 6 Nov 2024 (dealsite.co.kr)
  15. 15Dealsite – New owner SMG Youngmin Songdo; board changes — 24 Jul 2024 (dealsite.co.kr)
  16. 16Dealsite – Largest shareholder change; IcuRe relationship ends — 22 Jul 2024 (dealsite.co.kr)
  17. 17Top Daily – H1 2023 review opinion; lithium subsidiary — 16 Aug 2023 (topdaily.kr)
  18. 18Medigatenews – Clinomics–Cosnine MOU — 27 Jun 2023 (medigatenews.com)
  19. 19Dealsite – Trading resumes; IcuRe lock-up — 13 Mar 2023 (dealsite.co.kr)
  20. 20Newsis – Trading halt after largest shareholder sale — 31 Jan 2023 (newsis.com)
  21. 21Dealsite – Mask mandate; revenue rebound expectations — 20 Jan 2023 (dealsite.co.kr)
  22. 22Dealsite – Bunma Group cooperation — 20 Jul 2022 (dealsite.co.kr)
  23. 23Dealsite – Bunma investment talks — 22 Jul 2022 (dealsite.co.kr)
  24. 24Dealsite – IcuRe's control bid defeated — 24 Jun 2022 (dealsite.co.kr)
  25. 25Dealsite – IcuRe share sale; liquidity — 2023 (dealsite.co.kr)
  26. 26Asia Economy – IcuRe becomes largest shareholder — 7 Oct 2020 (core.asiae.co.kr)
  27. 27IB Tomato – Frequent name changes; chronic deficits — c.2021 (ibtomato.com)
  28. 28Etoday – 9Complex absorbs Cosnine — 8 Oct 2019 (etoday.co.kr)
  29. 29Infostock Daily – Absorption merger disclosure — 8 Oct 2019 (infostockdaily.co.kr)
  30. 30Etoday – CGMP renewal; credentials; Gerissong — 2019 (etoday.co.kr)
  31. 31Etoday – Cosnine CEO targets KRW 200bn — 21 Sep 2016 (etoday.co.kr)
  32. 32Korean Wikipedia – 코스나인 — accessed 2026 (ko.wikipedia.org)
  33. 33Saramin – Cosnine company history — accessed 2026 (saramin.co.kr)
  34. 34Hankyung Markets – Cosnine financial summary — accessed 2026 (markets.hankyung.com)
  35. 35Google Finance – 082660:KOSDAQ — accessed 2026 (google.com)
  36. 36Simply Wall St – Cosnine profile, health, ownership, management, valuation — data to 2024 (simplywall.st)
  37. 37Stockopedia – Cosnine share price — 2024 (stockopedia.com)
  38. 38StockHub – Cosnine — 2026 (stockhub.kr)
  39. 39THE VC – Cosnine company comparison — accessed 2026 (thevc.kr)
  40. 40Kukinews – Kolmar Korea and Cosmax record FY2025 — 26 Feb 2026 (kukinews.com)
  41. 41CNC News – Cosmax and Kolmar Korea FY2024 — 26 Feb 2025 (cncnews.co.kr)
  42. 42Bizwatch – Kolmar Korea and Cosmax FY2024 — 25 Feb 2025 (news.bizwatch.co.kr)
  43. 43Cosinkorea – 105 ODM companies' 2024 results — 24 Apr 2025 (cosinkorea.com)
  44. 44Hanwha Investment – Cosmecca Korea note — 7 Nov 2025 (file.alphasquare.co.kr)
  45. 45Alphadistill – Kolmar Korea coverage report — 2026 (alphadistill.com)
  46. 46Hankyung – IcuRe CEO interview — 10 May 2026 (hankyung.com)
  47. 47Hankyung – IcuRe rights issue to Solum Cosmetic — 30 Jun 2026 (hankyung.com)
  48. 48Hankyung – Coson renamed Yuhan Cosmetic — 27 Oct 2025 (hankyung.com)
  49. 49Insight – KOSDAQ delisting acceleration; thresholds — 25 Sep 2026 (insight.co.kr)
  50. 50MTN – Court rules market-cap delisting rule invalid — 2 Oct 2026 (news.mtn.co.kr)
  51. 51iNews24 – Audit disclaimers incl. Celestra (ex-Clinomics) — 2025 (inews24.com)
  52. 52Asia Economy – 18 listed firms with non-qualified opinions (SD Biotechnologies) — 28 Mar 2023 (core.asiae.co.kr)
  53. 53Korea Times – Korean cosmetics firms shift to North America — Mar 2023 (koreatimes.co.kr)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.